uniQure N.V. Ordinary Shares (QURE) Stock
Key stats
- Market cap
- $1.72B
- Price / Earnings ratio
- -6.8x
- EPS (TTM)
- -$3.51
- Volume
- Loading
- 52-week high
- $51.72
- 52-week low
- $8.73
Source: third-party data provider, as of November 13, 2026
Compare with QURE
Recent news

Uniqure Stock Falls After Its Huntington's Gene Therapy Lands At The FDA
Uniqure Stock Falls After Its Huntington's Gene Therapy Lands At The FDA
QURE

3 Promising Genomics Stocks to Add to Your Portfolio Now
3 Promising Genomics Stocks to Add to Your Portfolio Now
QURE

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop
QURE

uniQure Plunges on Additional Data From Huntington's Disease Study
uniQure Plunges on Additional Data From Huntington's Disease Study
QURE
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 48.57
- MACD 12/26/9
- -1.60
- EMA 9 of MACD
- -2.23
- MACD histogram
- 0.64
- SMA 50
- $30.35
- Price below SMA 50
- EMA 50
- $28.60
- Price below EMA 50
- SMA 200
- $29.63
- Price below SMA 200
- EMA 200
- $28.61
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.93 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Uniqure Stock Falls After Its Huntington's Gene Therapy Lands At The FDA
Uniqure Stock Falls After Its Huntington's Gene Therapy Lands At The FDA
QURE

3 Promising Genomics Stocks to Add to Your Portfolio Now
3 Promising Genomics Stocks to Add to Your Portfolio Now
QURE

UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop
QURE

uniQure Plunges on Additional Data From Huntington's Disease Study
uniQure Plunges on Additional Data From Huntington's Disease Study
QURE

uniQure Stock Crashed on Its Huntington's Data. Wall Street's Price Target Says the Selloff Went Too Far
uniQure Stock Crashed on Its Huntington's Data. Wall Street's Price Target Says the Selloff Went Too Far
QURE

QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data
QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data
QURE

uniQure BLA Filed as AMT-130 Shows 4-Year Huntington's Functional Benefit
uniQure BLA Filed as AMT-130 Shows 4-Year Huntington's Functional Benefit
QURE

QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law
QURE

Uniqure Plummets 40% On Another Shocking Twist For Its Huntington's Drug
Uniqure Plummets 40% On Another Shocking Twist For Its Huntington's Drug
QURE

UniQure's Huntington's therapy fails to significantly slow disease progression in trial
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
QURE
News tone: automated (AI) classification of the article's content, not a price prediction.
About uniQure N.V. Ordinary Shares
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Matthew Craig Kapusta CPA | CEO & Executive Director | 1972 |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | — |
| Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site | 1973 |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary | 1962 |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer | 1965 |
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations Officer | — |
| Mr. Richard Porter Ph.D. | Chief Business & Scientific Officer | 1968 |
| Ms. Chiara Elizabeth Russo | Senior Director of Investor Relations | — |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director | — |
| Ms. Erin Boyer | Chief People & Culture Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 48.57
- MACD 12/26/9
- -1.60
- EMA 9 of MACD
- -2.23
- MACD histogram
- 0.64
- SMA 50
- $30.35
- Price below SMA 50
- EMA 50
- $28.60
- Price below EMA 50
- SMA 200
- $29.63
- Price below SMA 200
- EMA 200
- $28.61
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $28.00
- Average
- $38.75
- High
- $48.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.4 | -21.5 | ||||||||||
| 2022 | -16.0 | -7.1 | +3.4 | -23.2 | -8.9 | +31.6 | +32.2 | -19.0 | -9.2 | -4.7 | +40.4 | -13.8 |
| 2023 | -2.7 | -3.1 | -6.4 | -3.9 | -4.1 | -44.4 | -12.3 | -18.0 | -23.1 | -7.8 | +17.7 | -5.2 |
| 2024 | -19.8 | +3.4 | -7.0 | -15.4 | +8.3 | -15.9 | +72.1 | -21.8 | -11.5 | +23.8 | +1.9 | +147.7 |
| 2025 | -12.8 | -16.5 | -2.8 | +48.9 | -3.5 | -3.8 | -0.5 | +19.2 | +243.2 | +23.1 | -19.8 | -9.9 |
| 2026 | -2.9 | -36.7 | +55.7 | +18.1 | +49.1 | +63.2 | -3.4 | +10.5 | -49.5 | +6.2 | +7.1 |



